Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.74
AMAG's Cash to Debt is ranked higher than
54% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. AMAG: 0.74 )
AMAG' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 0.74

Equity to Asset 0.41
AMAG's Equity to Asset is ranked higher than
59% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. AMAG: 0.41 )
AMAG' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.98
Current: 0.41

0.33
0.98
F-Score: 5
Z-Score: 1.43
M-Score: 5.17
WACC vs ROIC
7.08%
23.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 16.04
AMAG's Operating margin (%) is ranked higher than
92% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. AMAG: 16.04 )
AMAG' s 10-Year Operating margin (%) Range
Min: -18217.46   Max: 8.03
Current: 16.04

-18217.46
8.03
Net-margin (%) 80.71
AMAG's Net-margin (%) is ranked higher than
99% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. AMAG: 80.71 )
AMAG' s 10-Year Net-margin (%) Range
Min: -15420.63   Max: 109.19
Current: 80.71

-15420.63
109.19
ROE (%) 45.50
AMAG's ROE (%) is ranked higher than
98% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. AMAG: 45.50 )
AMAG' s 10-Year ROE (%) Range
Min: -86.79   Max: 42.96
Current: 45.5

-86.79
42.96
ROA (%) 17.89
AMAG's ROA (%) is ranked higher than
97% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. AMAG: 17.89 )
AMAG' s 10-Year ROA (%) Range
Min: -67.05   Max: 16.42
Current: 17.89

-67.05
16.42
ROC (Joel Greenblatt) (%) 382.68
AMAG's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. AMAG: 382.68 )
AMAG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1009.91   Max: 12.16
Current: 382.68

-1009.91
12.16
Revenue Growth (3Y)(%) 19.50
AMAG's Revenue Growth (3Y)(%) is ranked higher than
88% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. AMAG: 19.50 )
AMAG' s 10-Year Revenue Growth (3Y)(%) Range
Min: -31.2   Max: 265.9
Current: 19.5

-31.2
265.9
» AMAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

AMAG Guru Trades in Q2 2014

Jim Simons 129,060 sh (+3.12%)
Paul Tudor Jones Sold Out
» More
Q3 2014

AMAG Guru Trades in Q3 2014

Jim Simons Sold Out
» More
Q4 2014

AMAG Guru Trades in Q4 2014

Paul Tudor Jones 8,431 sh (New)
Ken Heebner 522,000 sh (New)
» More
Q1 2015

AMAG Guru Trades in Q1 2015

Paul Tudor Jones 38,762 sh (+359.76%)
Ken Heebner 522,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 15.20
AMAG's P/E(ttm) is ranked higher than
98% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMAG: 15.20 )
AMAG' s 10-Year P/E(ttm) Range
Min: 10.74   Max: 15.3
Current: 15.2

10.74
15.3
Forward P/E 833.33
AMAG's Forward P/E is ranked higher than
82% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMAG: 833.33 )
N/A
PE(NRI) 14.80
AMAG's PE(NRI) is ranked higher than
98% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMAG: 14.80 )
AMAG' s 10-Year PE(NRI) Range
Min: 10.73   Max: 14.85
Current: 14.8

10.73
14.85
P/B 3.80
AMAG's P/B is ranked higher than
77% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. AMAG: 3.80 )
AMAG' s 10-Year P/B Range
Min: 1.12   Max: 18.97
Current: 3.8

1.12
18.97
P/S 10.00
AMAG's P/S is ranked higher than
74% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. AMAG: 10.00 )
AMAG' s 10-Year P/S Range
Min: 3.62   Max: 496.73
Current: 10

3.62
496.73
PFCF 46.70
AMAG's PFCF is ranked higher than
92% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMAG: 46.70 )
AMAG' s 10-Year PFCF Range
Min: 36.32   Max: 351.64
Current: 46.7

36.32
351.64
POCF 46.01
AMAG's POCF is ranked higher than
92% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMAG: 46.01 )
AMAG' s 10-Year POCF Range
Min: 36.32   Max: 1268.5
Current: 46.01

36.32
1268.5
EV-to-EBIT 68.56
AMAG's EV-to-EBIT is ranked higher than
91% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMAG: 68.56 )
AMAG' s 10-Year EV-to-EBIT Range
Min: -542.7   Max: 84.8
Current: 68.56

-542.7
84.8
Current Ratio 3.12
AMAG's Current Ratio is ranked higher than
67% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. AMAG: 3.12 )
AMAG' s 10-Year Current Ratio Range
Min: 1.65   Max: 54.4
Current: 3.12

1.65
54.4
Quick Ratio 2.90
AMAG's Quick Ratio is ranked higher than
67% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. AMAG: 2.90 )
AMAG' s 10-Year Quick Ratio Range
Min: 1.4   Max: 54.33
Current: 2.9

1.4
54.33
Days Inventory 263.41
AMAG's Days Inventory is ranked higher than
80% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMAG: 263.41 )
AMAG' s 10-Year Days Inventory Range
Min: 6.05   Max: 1713.48
Current: 263.41

6.05
1713.48
Days Sales Outstanding 106.21
AMAG's Days Sales Outstanding is ranked higher than
75% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. AMAG: 106.21 )
AMAG' s 10-Year Days Sales Outstanding Range
Min: 4.86   Max: 863.25
Current: 106.21

4.86
863.25

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 7.30
AMAG's Price/DCF (Projected) is ranked higher than
90% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. AMAG: 7.30 )
AMAG' s 10-Year Price/DCF (Projected) Range
Min: 6.03   Max: 96.83
Current: 7.3

6.03
96.83
Price/Median PS Value 0.50
AMAG's Price/Median PS Value is ranked higher than
94% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. AMAG: 0.50 )
AMAG' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 75.57
Current: 0.5

0.15
75.57
Earnings Yield (Greenblatt) 1.50
AMAG's Earnings Yield (Greenblatt) is ranked higher than
88% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. AMAG: 1.50 )
AMAG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 1.5
Current: 1.5

1.2
1.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AMU.Germany,
AMAG Pharmaceuticals Inc is a Delaware corporation was founded in 1981. The Company is a specialty pharmaceutical company that markets Feraheme Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA, and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors who, in turn, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers and nephrology clinics. In addition, it also outsource a number of its product supply chain services to ICS, its third-party logistics provider, including services related to warehousing and inventory management, distribution, chargeback processing, accounts receivable management and customer service call center management. The Company is subject to extensive additional federal, state and foreign healthcare regulation, which includes but is not limited to, the Federal False Claims Act, the Federal Anti-Kickback Statute, the Foreign Corrupt Practices Act, and their state analogues, and similar laws in countries outside of the U.S.
» More Articles for AMAG

Headlines

Articles On GuruFocus.com
AMAG Pharmaceuticals Inc. (AMAG) EVP, CFO David Arkowitz sells 2,705 Shares Feb 28 2011 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 230,011 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. (AMAG) CFO and Chief Business Officer David Arkowitz sells 4,459 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2009 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 5,000 Shares Aug 05 2009 

More From Other Websites
AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth May 20 2015
AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth May 20 2015
AMAG PHARMACEUTICALS INC. Financials May 15 2015
AMAG Pharmaceuticals, Inc. to Participate in the UBS Global Healthcare Conference May 13 2015
AMAG Pharmaceuticals, Inc. to Participate in the UBS Global Healthcare Conference May 13 2015
10-Q for AMAG Pharmaceuticals, Inc. May 08 2015
Zacks Rank #5 Additions for Friday - Tale of the Tape May 08 2015
AMAG PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report May 06 2015
AMAG Beats on Q1 Earnings & Revenues, Ups View - Analyst Blog May 06 2015
AMAG Pharmaceuticals Reports Record First Quarter 2015 Financial Results and Increases Financial... May 05 2015
AMAG Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today May 05 2015
AMAG Pharmaceuticals tops Street 1Q forecasts May 05 2015
AMAG Pharmaceuticals tops Street 1Q forecasts May 05 2015
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2015
Q1 2015 AMAG Pharmaceuticals Inc Earnings Release - Before Market Open May 05 2015
AMAG Pharmaceuticals Reports Record First Quarter 2015 Financial Results and Increases Financial... May 05 2015
AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences Apr 29 2015
AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences Apr 29 2015
AMAG Pharmaceuticals, Inc. to Host Conference Call on May 5, 2015 at 8:00 a.m. ET to Discuss... Apr 22 2015
AMAG Pharmaceuticals, Inc. to Host Conference Call on May 5, 2015 at 8:00 a.m. ET to Discuss... Apr 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK